HK Stock Market Move | BIOCYTOGEN-B(02315) rose more than 5% during trading today. The company has successfully listed on the science and technology innovation board, building a dual A+H platform for listing.

BIOCYTOGEN-B (02315) rose more than 5% during the trading session, and as of the time of writing, it rose by 4.15% to 28.12 Hong Kong dollars, with a turnover of 19.5098 million Hong Kong dollars. On the news front, on December 10th, Bai Ao Sai Tu was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board. This is a key step for Bai Ao Sai Tu after its listing on the HKEX on September 1, 2022, in deepening its capital market layout and enhancing corporate value, marking the successful construction of a dual-platform listing pattern of "H+A". Western released a research report stating that the company initiated the "Thousand Mice and Ten Antibodies" project in March 2020, using an "antibody shelf" model, which not only saved research and development time and reduced uncertainty in early development, but also compared multiple targets in parallel at the source, which may help pharmaceutical companies improve research and development efficiency and the success rate of clinical transformation. The company's antibody business started in 2020 with an annual revenue of 41 million yuan, and by the first half of 2025, the revenue reached 163 million yuan, a year-on-year increase of 37.8%. With further clinical advancement of subsequent molecules, the company's platform value is expected to further expand.